Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation

Chinese Journal of Pathology

Volumn 42, Issue 4, 2013, Pages 252-256

  Zhong, Shan ^a   Zhang, Hai Ping ^a   Zheng, Jie ^a   Bai, Dong Yu ^a   Fu, Li ^a   Chen, Pei Qiong ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Carcinoma, non small cell lung; Lung neoplasms; Microtubule associated proteins; Oncogene fusion

Indexed keywords

EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SEX DIFFERENCE; SMOKING; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84878636238     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2013.04.009     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2006, 56(2):106-130.
2. Mok TS, Wu YL, Thongprasert S, et al. Cefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10):947-957.
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONC-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8):735-742.
4. Sun Y, Shi Y, Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced nonsmall cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Onco, 2011, 29 (Suppl): [abstr 7522].
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(8):561-566. (Pubitemid 47206930)
6. Horn L, Pao W. EML4-ALK: honing in on a new target in nonsmall-cell lung cancer. J Clin Oncol, 2009, 27(26):4232-4235.
7. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Nad Acad Sci USA, 2008, 105(50):19893-19897.
8. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol, 2011, 12(11):1004-1012.
9. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with de\elopment of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010, 9:188.
10. Ren S, Chen X, Kuang P, et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer, 2012, 118(22):5588-5594.
11. Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female non-smoker asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys, 2012, 64(2):155-160.
12. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with nonsmall cell lung cancer (NSCLC) (abstract). 2010 ASCO Annual Meeting. J Clin Oncol, 2010, 28(suppl):18.
13. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 2010, 46(10):1773-1780.
14. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol, 2010, 17(3):889-897.
15. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26):4247-4253.
16. Zhang XC, Zhang S, Yang XN, et al. Multiple EML4-ALK fusion transcripts and concurrent EGFR kinase mutation in Chinese nonsmall cell lung cancer. J Thorac Oncol, 2009, 4(9):S549.